Characterization of Tumor Responses in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib in the Phase 3 Randomized Trial: REFLECT
Sign Up to like & getrecommendations! Published in 2024 at "Liver Cancer"
DOI: 10.1159/000537947
Abstract: Abstract Introduction: In REFLECT, lenvatinib was noninferior to sorafenib in terms of overall survival (OS) in patients with unresectable hepatocellular carcinoma (uHCC; median 13.6 vs. 12.3 months; HR 0.92, 95% CI 0.79–1.06). The objective response… read more here.
Keywords: response; per recist; tumor responses; recist ... See more keywords
Inter-reader agreement of RECIST and mRECIST criteria for assessing response to transarterial chemoembolization in hepatocellular carcinoma
Sign Up to like & getrecommendations! Published in 2025 at "BMC Medical Imaging"
DOI: 10.1186/s12880-025-01688-z
Abstract: To evaluate the reproducibilities of Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST (mRECIST) for hepatocellular carcinoma (HCC) patients treated with transarterial chemoembolization (TACE) using contrast-enhanced computed tomography (CT). This retrospective study included… read more here.
Keywords: inter reader; recist mrecist; response; mrecist ... See more keywords